Product Launches
CorVista Health Ships PCWP Add-On and Clinical Decision Support for Guideline-Driven Cardiac Care
By News Desk ·
Key takeaways
- CorVista Health launched CorVista Clinical Decision Support and made the PCWP Add-On commercially available in the U.S.
- The PCWP Add-On, FDA-cleared in July 2026, uses an AI-based algorithm on the same 3.5-minute resting acquisition as the CAD and PH algorithms.
- CorVista CDS pairs test results with published guidelines to give providers an estimated post-test probability for coronary artery disease and next-step recommendations.
- Category III CPT code 1104T took effect October 1, 2026, supporting reporting for the CorVista System across CAD, PH and elevated PCWP.
CorVista Health launched CorVista Clinical Decision Support and made its PCWP Add-On commercially available in the U.S., the company said on November 18, 2026. The add-on, FDA-cleared in July 2026, gives providers a noninvasive indicator of elevated pulmonary capillary wedge pressure, a key indicator of possible heart failure. Business Wire published the announcement.
How CorVista Clinical Decision Support Works
CorVista Health said CDS works in three steps. The physician first enters the patient's age, sex, symptoms and cardiovascular risk factors to establish a pre-test probability from established clinical guidelines. The CorVista System results from its FDA-cleared CAD, PH and PCWP algorithms are then applied using statistical performance from validated clinical studies. CDS returns the estimated CAD post-test probability plus the guideline recommendations that match the patient's combination of results.
The PCWP Add-On uses an AI-based algorithm to indicate the likelihood of elevated PCWP from the same 3.5-minute resting acquisition used for the CAD and PH algorithms. Elevated PCWP is a key indicator of possible heart failure, including HFrEF and HFpEF, which combined affect an estimated 7.7 million U.S. adults. HFpEF is estimated to account for more than half of heart failure cases and remains underdiagnosed, according to the announcement.
Adrian Lam, President and Chief Executive Officer of CorVista Health, said: "Providing more data is not necessarily enough; a diagnostic result only creates value when it delivers actionable insights leading to the right next step in care." Charles R. Bridges, M.D., Sc.D., Executive Vice President and Chief Scientific Officer, said adding PCWP means more patients with suspected heart failure, particularly HFpEF, can be identified earlier and routed to the appropriate care pathway.
CorVista's Funding and Clinical Scale
According to akta.pro company records, CorVista Health has raised $94 million in total funding across four rounds, the last a $65 million Series C in March 2021. The same records list clinical trials involving more than 11,000 patients for the CorVista-PH test, which received FDA breakthrough designation. Each CorVista test requires 3.5 minutes to capture cardiovascular data, with results delivered through the physician web portal in less than 30 minutes.
FDA Clearances Behind the PCWP Launch
The FDA cleared the CorVista System PCWP Add-On in July 2026, a clearance MedTech World described as expanding AI-powered noninvasive heart failure assessment. In July 2026, CorVista Health and Mayo Clinic announced a research collaboration to evaluate the CorVista-PH test in a prospective observational trial, Mpo-mag reported. The American Medical Association granted Category III CPT code 1104T for the CorVista System in July 2026, FinancialContent reported.
CPT Code 1104T Takes Effect
Category III CPT code 1104T is effective as of October 1, 2026, and supports reporting for use of the CorVista System in assessing potential CAD, PH and elevated PCWP using augmentative algorithmic analysis of orthogonal voltage gradient and photoplethysmography signals. CorVista Clinical Decision Support is a separate application, independent of the FDA-cleared CorVista System.